Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis
Use trametinib, authorised either as monotherapy or combined with dabrafenib, with caution in patients with risk factors for gastrointestinal perforation.
Letters sent to healthcare professionals in February 2016
In February 2016, a letter was sent to healthcare professionals regarding medicines containing valproate.